President Trump announced the winners of the “FAKE NEWS” awards on Wednesday, after much anticipation — especially from the news media. But the Republican National Committee (RNC) page the president linked to at roughly 8 p.m. on Wednesday came up with an error message shortly afterward.
San Antonio-Four new businesses from Chile will be opening up shop in San Antonio in late 2018, joining a program run by the emerging technology startup center, VelocityTX.
VelocityTX, a resource center for entrepreneurs and startups that’s also trying to attract more businesses to San Antonio, is planning to bring four companies from a group of 10 that graduated last week from an institution called Austral Incuba, an incubator run by Universidad Austral de Chile, a university in Valdivia, Chile. Velocity TX and Austral Incuba decided last year to partner on a program they call 6+3, where graduates of… Read more »
UNDERWRITERS AND PARTNERS
BIO’s Industry Analysis team has released its first report in a new series on the state of innovation in highly prevalent chronic diseases.
The new series of reports will dig deeper into a previously observed phenomenon: less venture dollars are heading into chronic diseases. BIO’s previous research showed recent increases in venture funding heading into oncology and rare disease, leaving highly prevalent, chronic disease behind. Disease area examples include psychiatric disorders, endocrine, cardiovascular, and respiratory diseases as shown in the figure below.
Figure 1. Annual costs vs. a decade of venture capital funding (2007-2016) for Oncology, and other highly prevalent, chronic diseases. [Source for prevalence: Psychiatric Source for healthcare cost: Health Affairs, 35, No. 6 (2016). Source of venture data: BIO Industry Analysis, Emerging Company Trend Report, 2017.]
The persistence of this trend could have implications for the future output of innovative medicines in these disease areas. The cause for concern is magnified by the impact these chronic disease areas are having on the overall healthcare system (as shown in $ Billions in the figure above).
Depression, the first in a series of reports on the current funding and R&D landscape of highly prevalent, chronic diseases, takes an in-depth look at the state of innovation in depression therapeutics. As one of the most prevalent psychiatric disorders, depression impacts 16 million patients in the United States and is estimated to cost our health care system $105 billion annually.
The report is available for download here, where you can also sign up to receive future BIO Industry Analysis reports as they are released.
Key Takeaways
The next report in the series will focus on pain and addiction. Opioids will be covered in the report and a special session on the opioid epidemic will be featured at the BIO CEO & Investor Conference next month, February 12-13 in New York City. month, February 12-13, in New York City. The session will explore the most promising avenues in the neuroscience of addiction and alternatives to opioid-based pain management, as well as identify the most pressing bottlenecks in our understanding of the brain’s addiction to painkillers. Register today!
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-CHILD-AG-2016Pillar: REC Programme 2014-2020Opening Date: Deadline: Tue, 13 Dec 2016 17:00:00 (Brussels local time)Modification Date: Wed, 17 Jan 2018Latest information: Abstracts of successful proposalsare available under the Topic conditions and document (Additional documents).
Titan Spine, a Mequon, WI-based company that sells surgical implants designed for spinal surgeons to use when operating on patients, raised more than $7.8 million from investors across two separate funding rounds that closed in late December.
Titan’s products include a line of titanium “Endoskeleton” cages that are implanted to stabilize a patient’s spinal cord following the surgical removal of damaged vertebrae or the treatment of other conditions.
Co-founder and CEO Peter Ullrich says Titan plans to use some of the new money to fuel its continued growth. The company now has about 110 employees, says Ullrich, who estimates revenues from… Read more »
UNDERWRITERS AND PARTNERS
An Eiger BioPharmaceuticals drug being tested for the treatment of pulmonary arterial hypertension has failed a mid-stage study, and the drug developer says it will stop work on the compound for that condition.
News of the clinical trial failure cut the value of shares in Palo Alto, CA, based Eiger (NASDAQ: EIGR) nearly in half. The company’s stock price closed at $8.10 Tuesday, down 49.3 percent from last Friday’s closing price.
In pulmonary arterial hypertension (PAH), high blood pressure develops in the arteries that carry blood to the lungs. The condition leads to shortness of breath, chest pain, and fainting…. Read more »
UNDERWRITERS AND PARTNERS
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-CIP-2016-2017Pillar: Societal ChallengesOpening Date: Deadline: Thu, 25 Aug 2016 17:00:00 (Brussels local time)Modification Date: Tue, 16 Jan 2018Latest information: An overview of the evaluation results (flash call info) is now available under the ‘Additional documents’ section on the topic page.
Since 2006, the Medicare prescription drug program – known as Medicare Part D – has provided America’s seniors and disabled individuals with access to a wide range of affordable medicines. By relying on market-based competition, this program has achieved substantial savings for taxpayers and helped provide affordable medicines to our most vulnerable population.
To learn more about the success of the Medicare Part D program, check out our new infographic: click here.
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-VAW-AG-2016Pillar: REC Programme 2014-2020Opening Date: Deadline: Wed, 8 Mar 2017 17:00:00 (Brussels local time)Modification Date: Mon, 15 Jan 2018Latest information: Abstracts of selected proposals are publishedin the section Topic conditions and documents (Additional documents).
Juno Therapeutics (NASDAQ: JUNO) has appointed Cindy Elkins to serve as chief information officer. Elkins comes to the Seattle cancer immunotherapy developer from Genentech, where she was vice president, IT, for the Americas. Before Genentech, Elkins worked at software and IT services firm Ariba.
UNDERWRITERS AND PARTNERS
